Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Randomized, Placebo-Controlled Study of the Safety, Antiviral & Immunomodulatory Activity of Broadly Neutralizing Antibodies 3BNC117-LS-J and 10-1074-LS-J in Combination in ART-treated Adults in Sub-Saharan Africa Living With HIV During a Monitored Analytical Treatment Interruption

NCT06031272 is registered in ClinicalTrials.gov with Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections as lead sponsor.

NCT NCT06031272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06031272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Randomized, Placebo-Controlled Study of the Safety, Antiviral & Immunomodulatory Activity of Broadly Neutralizing Antibodies 3BNC117-LS-J and 10-1074-LS-J in Combination in ART-treated Adults in Sub-Saharan Africa Living With HIV During a Monitored Analytical Treatment Interruption
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Phase
Phase 1
Overall status
Completed
Start date
May 28, 2024
Completion date
June 25, 2026
Enrollment
32 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1-infection